Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

ng those caused by MRSA, as well as community acquired pneumonia. Novexel's future clinical development with NXL103 is expected to focus on its potential to be used in hospitals as an oral agent for the treatment of infections caused by Gram positive organisms, including resistant pathogens such as MRSA. Currently, physicians have a very limited choice of anti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being discharged from the hospital.

In the second quarter of 2008 sanofi-aventis elected not to exercise its option to develop and commercialise NXL103. Consequently, worldwide rights to the NXL103 programme are retained by Novexel.

Iain Buchanan, Novexel's CEO, commenting on the announcement said, "We are very pleased that the results from our first Phase II clinical trial with NXL103 are positive. The data from this trial confirm the efficacy of NXL103 in patients with mild to moderate CAP. Furthermore, the pre-clinical and clinical work that we have carried out to-date with NXL103 provides a compelling platform for Phase III development. We believe that with its potent activity against MRSA, NXL103 may offer physicians an important therapeutic option when they switch patients from IV to oral treatment prior to discharge from the hospital."

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel anti-bacterials designed to overcome the significant global problem of bacterial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the in
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... VIEJO , Kalifornien, 20. Mai 2013 ... bekannt, dass das Unternehmen die CE-Kennzeichnung für ... zur Embolisation von Aneurysmen erhalten hat. Das ... Europa bereits mit der kontrollierten Einführung dieser ... bietet die SL-Produktfamilie auch ein verbessertes Handling, ...
(Date:5/20/2013)... 20, 2013  Atlantic Pharmaceuticals, Inc., a specialty ... a unique technology to deter prescription drug abuse ... Anthony Soscia , has been chosen ... Chronicle ,s Health-Care Heroes Awards. The awards are ... to honor individuals and organizations demonstrating excellence and ...
(Date:5/20/2013)... YORK , LONDON , ... , May 20, 2013 ... of Osteoarthritis and Preference for Minimally Invasive Procedures to ... landscape, and market trends for the six arthroscopy device ... (FMSs), arthroscopy implants, arthroscopy radio frequency systems, and arthroscopy ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4
... Oct. 29 Stryker Corporation (NYSE: SYK ... a division of Porex Corporation. Porex Surgical is a ... (PPE) for use primarily in reconstructive surgery of the ... the PPE market with strong brand recognition and considerable ...
... LEIDEN, Netherlands, Oct. 29 Pursuant to the provisions of ... Takeover Bids (Besluit Openbare Biedingen Wft) requiring a public announcement ... offer to provide a status update, Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) provide the following ...
Cached Medicine Technology:Stryker Announces Acquisition of Privately-Held Porex Surgical 2Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 2Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 3Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 4Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 5
(Date:5/20/2013)... May 20, 2013 ... will be holding a lupus ... on June 10th. , Meeting ... 6:30 p.m. – 8 p.m., ... from Sparrow Hospital),                  1200 ...
(Date:5/20/2013)... 20, 2013 yurbuds®, maker of the ... today announced the launch of its new Signature Series ... Jacobs, with more signature athletes to come. Created with ... Series ITE 100 is the perfect training partner for ... 100 features reflective, tangle-resistant Kevlar cords, premium sound quality ...
(Date:5/20/2013)... at Galveston researchers have been awarded a five-year, $1.8 ... and Stroke to apply the techniques of gene therapy ... pain that arises from a malfunction in the nervous ... for millions of Americans, manifesting itself in a variety ... feel intense discomfort in response to a light touch, ...
(Date:5/20/2013)... 20, 2013 Stemedica Cell ... stem cell manufacturing, research and development, announced today ... and Director of Interventional Cardiology Research at the ... Scientific and Medical Advisory Board for Stemedica’s Cardiology ... Dr. Wilensky divides his time between the cardiac ...
(Date:5/20/2013)... York (PRWEB) May 20, 2013 The nationwide ... study has found that magnetic resonance imaging (MRI) can be ... of whether or not patients are experiencing symptoms. According ... Journal of Bone & Joint Surgery, MRI detected synovitis (tissue ... patients suffering symptoms due to mechanical causes, the detection rate ...
Breaking Medicine News(10 mins):Health News:yurbuds Expands Best-Selling Lines with Innovative New Products 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 2Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4
... by ticks , THURSDAY, Oct. 4 (HealthDay News) -- Many ... may actually have been bitten by another tick and have ... "It is striking how often re-infection appears to occur," lead ... York Medical College, said in a prepared statement. "Our findings ...
... Institute of Child Health and Human Development (NICHD) announced ... was awarded a competitive contract to participate in the ... be conducted in the United States to assess the ... human health. The study will follow 100,000 children from ...
... A 1998 settlement designed to limit the marketing of smokeless ... University of Georgia study published in the early online edition ... rates are significant and have been very stable over the ... the UGA Grady College of Journalism and Mass Communication. We ...
... Oct. 4 Nastech Pharmaceutical,Company Inc. (Nasdaq: ... "Rick",Costantino, Ph.D., to Chief Scientific Officer of Delivery. ... development of new,drug delivery technologies for peptide and ... since 2003, is retiring,tomorrow, October 5, 2007, as ...
... Energizer has forged a,national partnership with Susan ... its,encouraging message-the Power to Keep Going(R)-to more than ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071004/AQTH013 ) Officials with ... a,special one. Energizer is the battery known around ...
... which a cell protein protects cancer cells,from a ... target for,improving treatment outcomes for patients., A team ... Medical Research (CCIA), led,by Associate Professor Maria Kavallaris, ... could play an important role in resistance to ...
Cached Medicine News:Health News:Lyme Disease Relapse Often a New Infection 2Health News:UMASS Medical School awarded National Children's Study contract 2Health News:UMASS Medical School awarded National Children's Study contract 3Health News:UMASS Medical School awarded National Children's Study contract 4Health News:UGA study: Youth exposed to smokeless tobacco ads despite settlement 2Health News:UGA study: Youth exposed to smokeless tobacco ads despite settlement 3Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 3Health News:Energizer Joins Roster of Susan G. Komen Race for the Cure(R) National Sponsors; Energizer(R) ReTreat Pampers Cancer Survivors With Traveling Mini-Spa 2Health News:Energizer Joins Roster of Susan G. Komen Race for the Cure(R) National Sponsors; Energizer(R) ReTreat Pampers Cancer Survivors With Traveling Mini-Spa 3Health News:Cell skeleton may hold key to overcoming drug resistance in cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: